Crohn's Disease Biologic Denied: Appeal Guide
Crohn's disease biologic denied by insurance? Appeal with step therapy records, colonoscopy evidence, and ACG guidelines. This guide covers every angle.
Crohn's disease is a chronic inflammatory bowel disease (IBD) that can affect any segment of the gastrointestinal tract. For patients with moderate-to-severe Crohn's, biologic therapies — including adalimumab (Humira), infliximab (Remicade), vedolizumab (Entyvio), ustekinumab (Stelara), and risankizumab (Skyrizi) — are clinically proven to induce and maintain remission, heal the intestinal lining, and prevent surgery. Insurance denials for these drugs are frustratingly common and can carry serious health consequences.
Why Insurers Deny Crohn's Biologics
Incomplete step therapy. Most commercial insurers require that patients try and fail at least two conventional therapies before a biologic is approved: aminosalicylates (5-ASA compounds like mesalamine), corticosteroids (prednisone, budesonide), and immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate). The insurer may claim that not all steps were completed or that trials weren't long enough.
Severity not documented. Insurers may deny if the severity of disease isn't captured with objective measures — Crohn's Disease Activity Index (CDAI), Harvey-Bradshaw Index, or endoscopic findings (SES-CD score, ulcer burden on colonoscopy, fistula documentation).
Switching biologics. Moving from one biologic to another (e.g., anti-TNF to vedolizumab or ustekinumab after primary non-response or secondary loss of response) requires documented evidence of failure on the first agent.
Non-preferred agent. The insurer may prefer a biosimilar of infliximab or adalimumab and deny brand-name agents or non-TNF biologics unless step therapy through the preferred agent is completed.
Building Your Clinical Appeal
Document Conventional Therapy Failures
Compile records showing each conventional therapy, the dose used, the duration, and why it failed. For azathioprine or 6-MP, include lab documentation of adequate dosing (thiopurine metabolite levels if tested). If immunomodulators were contraindicated (e.g., risk of lymphoma in young men, thiopurine methyltransferase [TPMT] deficiency, pancreatitis history), document that contraindication explicitly to justify bypassing that step.
Submit Objective Endoscopic Evidence
Colonoscopy reports documenting mucosal inflammation, ulceration, stricturing, or fistulizing disease are powerful evidence. The ACG (American College of Gastroenterology) guidelines emphasize treat-to-target strategies aimed at mucosal healing — not just symptom control. If colonoscopy shows active inflammation despite conventional therapy, include that report in full.
Fistulizing Disease: A Compelling Special Case
Perianal fistulizing Crohn's disease responds poorly to 5-ASA and immunomodulators alone. Biologics — particularly infliximab — have the strongest evidence for fistula closure and are endorsed by ACG guidelines as first-line for fistulizing disease. If your Crohn's is fistulizing, argue explicitly that step therapy through aminosalicylates does not apply, and cite the ACG guideline recommendation for early anti-TNF therapy in perianal disease.
Use Validated Disease Activity Indices
Include CDAI scores (moderate disease: 220–450; severe: >450) or Harvey-Bradshaw Index scores in your medical records. If your gastroenterologist hasn't formally scored these, request a letter of medical necessity that includes current disease severity assessment. CRP and fecal calprotectin levels corroborating active inflammation support the case.
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
Cite ACG and AGA Guidelines
The American College of Gastroenterology's Crohn's disease guidelines and the American Gastroenterological Association's clinical practice updates recommend biologics (anti-TNFs, vedolizumab, ustekinumab, risankizumab) for moderate-to-severe Crohn's disease. Ustekinumab and risankizumab have evidence for patients who fail anti-TNFs. These guidelines are evidence-based and widely recognized as the standard of care — include citations in your appeal.
Document Steroid Dependence
If your patient has required repeated or prolonged courses of corticosteroids to control symptoms, this is strong evidence for biologic therapy. The goal of biologic treatment is to achieve steroid-free remission. Document steroid use with dates, doses, and duration; insurers and External Independent Review: Complete Guide" class="auto-link">external reviewers recognize steroid dependence as a marker of moderate-to-severe disease.
Hospitalization and Surgical History
Prior hospitalizations for Crohn's flares, bowel obstructions, or surgeries (bowel resections, strictureplasties) demonstrate disease severity and the high cost of under-treatment. Include discharge summaries in your appeal. The argument: a biologic that maintains remission is less expensive than repeated hospitalizations and surgery.
Regulatory Protections and Resources
Step therapy override laws apply in many states — if you've already tried and failed required drugs, or if they're contraindicated, request a step therapy override in writing.
External independent review — if your internal appeal is denied, escalate to your state's external review process. An independent gastroenterologist applying ACG standards is likely to find biologic therapy medically necessary.
Manufacturer assistance programs — AbbVie (myAbbVie Assist for Humira), Janssen (CarePath for Stelara), Takeda (Takeda Together for Entyvio), and AbbVie (Skyrizi Co-Pay Card) all offer free medication during the appeals process and patient assistance for uninsured patients.
- Crohn's & Colitis Foundation (crohnscolitisfoundation.org) — insurance advocacy resources, case managers
- IBD Healthline — patient community and insurer navigation resources
A well-documented appeal citing objective clinical findings, established guidelines, and the medical and economic cost of biologic denial wins the majority of Crohn's biologic cases.
Fight Back With ClaimBack
ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word. Fight your denial at ClaimBack →
Related Reading:
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides